Potential For US Requiring Supplement Registration Underscored During FDA’s Hiatus From Inspections
Executive Summary
FDA’s pause in facility inspections could prompt draft legislation for mandatory supplement product registration. It told industry groups it’s working on language for legislation to give it a better handle on products in the market and facilities with problems, says CRN head Steve Mister.
You may also be interested in...
Supplement OWL Progress: Mirror For Industry Support For Transparency, Mandatory Registration?
Advisory board for CRN-operated Supplement OWL recently reached out to industry for “ultimate reason” of recruiting participation. “Transparency has never been more important and this registry is a demonstration of this industry’s commitment to candor and honesty with our regulators, retailers and consumers,” they say.
US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements
Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.
NDI Or GRAS? Supplement Label But A Drug Claim? Answers Unclear For Some Regulatory Questions
“We try to interpret the language that is given to us and if Congress would make it more clear to us, we would absolutely carry that forward,” ODSP's Cara Welch says about whether FDA regulations require NID notifications or self-GRAS submissions for dietary ingredients yet to be used in supplements.